Thoratec Presentation at Raymond James Conference to Be Webcast
PLEASANTON, Calif., March 3 /PRNewswire-FirstCall/ -- Thoratec Corporation
(Nasdaq: THOR), a world leader in device-based mechanical circulatory support
therapies to save, support and restore failing hearts, said today that it will
be participating in the Raymond James 30th Annual Institutional Investors
Conference on Monday, March 9.
David Smith, executive vice president and chief financial officer, will
provide an update on the company, beginning at 8:05 a.m., Eastern Daylight
Time, (5:05 a.m., Pacific Daylight Time).
Thoratec is a world leader in therapies to address advanced-stage heart
failure. The company's product lines include the Thoratec(R) VAD (Ventricular
Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with
more than 12,000 devices implanted in patients suffering from heart failure.
Additionally, its International Technidyne Corporation (ITC) division supplies
point-of-care blood testing and skin incision products. Thoratec is
headquartered in Pleasanton, California. For more information, visit the
company's web sites at http://www.thoratec.com or http://www.itcmed.com.